市場調查報告書
商品編碼
1511363
到 2030 年原代細胞培養市場預測:按產品、細胞類型、分離方法、應用、最終用戶和地區進行的全球分析Primary Cell Culture Market Forecasts to 2030 - Global Analysis By Product (Primary Cells, Reagents and Supplements and Other Products), Cell Type (Human Cells and Animal Cells), Separation Method, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2024 年全球原代細胞培養市場規模為 56.2 億美元,預計預測期內複合年成長率為 15.3%,到 2030 年將達到 131.9 億美元。
原代細胞培養是指直接從組織或生物體分離細胞並在受控條件下進行試管內培養的過程。此方法保留了細胞的大部分生理、生化和遺傳特性,並提供了密切模擬體內條件的培養物。然而,原代培養細胞的壽命有限,通常具有有限的分裂次數。
根據世界衛生組織預測,全球癌症死亡人數將持續增加,到2030年將達到1,700萬以上。
不斷成長的製藥和生物技術產業
製藥和生物技術領域的成長正在推動原代細胞培養市場,刺激了對創新和可靠的細胞模型的需求。這些領域需要高品質的原代細胞來進行藥物發現、開發和測試,因為與永生化細胞株相比,它們提供了更多的生理相關資料。個人化醫療和再生療法的進步進一步增加了對特定原代細胞的需求。此外,對生技藥品和生物相似藥的日益關注需要使用原代細胞來評估藥物功效和安全性。
有限的可用率
原代細胞培養市場的供應有限是指採購和取得原代細胞用於研究和生產的挑戰。原代細胞非常稀有且昂貴,因為它們直接源自組織並且壽命有限。分離過程在技術上很困難,只能產生有限數量的活細胞。此外,捐助者的可變性、道德考慮和嚴格的監管要求進一步限制了其可用性。
3D 細胞培養的進展
3D 細胞培養技術的進步正在顯著增強原代細胞培養市場。與傳統的 2D 培養相比,這些技術透過更好地模仿體內環境,提供了更生理相關的模型。基於支架的系統、球體和類器官等創新可以實現更精確的細胞-細胞和細胞-基質相互作用。這將導致疾病建模、藥物篩檢和組織工程應用的改進。此外,3D 培養可支持原代細胞的生長,保留其分化狀態和功能,使它們對個人化醫療和再生治療有價值。
再現性和標準化問題
再現性和標準化是原代細胞培養市場的關鍵問題。直接源自組織的原代細胞表現出固有的生物變異性,導致實驗結果不一致。標準化問題源自於缺乏統一的協議和品管,使得難以確保不同實驗室和實驗的一致性。這些挑戰可能會妨礙研究結果的可靠性,影響基於細胞的檢測的開發,並使監管核准複雜化。
COVID-19 大流行對原代細胞培養市場產生了重大影響,主要是透過供應鏈中斷和實驗室操作延誤。對 SARS-CoV-2 相關研究的需求不斷成長,推動了市場成長,原代細胞培養對於研究病毒行為、開發疫苗和測試抗病毒藥物至關重要。各研究所將重點轉向 COVID-19 研究,加速細胞培養技術的創新和資金籌措。然而,我們對流行病相關研究的關注導致了非 COVID-19 研究的延誤,影響了我們的整體研究管道和計劃時間表。
預計原電池產業在預測期內將是最大的
原代細胞培養市場中原代細胞細分市場的成長歸因於多種因素。對於用於藥物開發和測試的更生理相關的細胞模型的需求不斷成長,而原代細胞可以提供這一點,因為它們是直接從組織中提取的。該領域受益於維持細胞完整性和功能的分離技術的進步,提高了效用。此外,與永生化細胞株相比,原代細胞使研究人員能夠更精確地研究複雜的細胞間相互作用和疾病機制。
酵素分解領域預計在預測期內複合年成長率最高
原代細胞培養市場中的酵素分解是在細胞培養過程中使用酵素將細胞從組織中解離或分解不必要的細胞成分的過程。該領域的成長是由於對高效、良性細胞分離和維護方法的需求不斷成長而推動的。胰蛋白酶、膠原蛋白酶和分散酶等酶對於以最小的損傷實現高細胞產量至關重要,從而支持研究、藥物開發和再生醫學中的各種應用。酵素技術的進步,包括重組酶的開發和改進的配方,使酵素消化方法更加可靠和具體。
由於多種因素,北美地區的原代細胞培養市場正在經歷顯著成長。首先,生物技術和製藥領域的研發活動不斷增加,推動了藥物發現和藥物開發對原代細胞培養技術的需求。慢性病的增加和個人化醫療的需求強調了原代細胞培養在研究疾病機制和開發標靶治療中的重要性。此外,學術機構、研究機構和產業相關人員之間的合作透過促進知識交流為該地區的發展做出了貢獻。
由於多種因素,亞太地區的原代細胞培養市場正在經歷顯著成長。需求受到中國、印度、日本和韓國等國家生物技術和製藥業投資增加的推動。這些國家正在擴大其研究能力和基礎設施,並培育適合細胞培養技術的環境。此外,慢性病盛行率的上升推動了對藥物開發高級研究的需求,進一步推動了市場的發展。
According to Stratistics MRC, the Global Primary Cell Culture Market is accounted for $5.62 billion in 2024 and is expected to reach $13.19 billion by 2030 growing at a CAGR of 15.3% during the forecast period. Primary cell culture refers to the process of isolating cells directly from a tissue or organism and growing them in vitro under controlled conditions. This method provides a culture that closely mimics the in vivo state of the cells, retaining most of their physiological, biochemical, and genetic characteristics. However, primary cultures have a limited lifespan and usually undergo senescence after a finite number of divisions.
According to WHO projections, the number of cancer deaths worldwide will continue to climb and will reach over 17 million by 2030.
Growing pharmaceutical and biotech sectors
The growing pharmaceutical and biotech sectors are driving the primary cell culture market by fueling the demand for innovative and reliable cell-based models. These sectors require high-quality primary cells for drug discovery, development, and testing, as they provide more physiologically relevant data compared to immortalized cell lines. Advances in personalized medicine and regenerative therapies further amplify the need for specific primary cells. Additionally, the increasing focus on biologics and biosimilars necessitates the use of primary cells to evaluate drug efficacy and safety.
Limited availability
The limited availability restraint in the Primary Cell Culture Market refers to the challenges in sourcing and obtaining primary cells for research and production. Primary cells are derived directly from tissues and have a finite lifespan, making them scarce and expensive. Isolation processes can be technically demanding and may yield limited quantities of viable cells. Additionally, donor variability, ethical considerations, and stringent regulatory requirements further restrict their availability.
Advancements in 3D cell culture
Advancements in 3D cell culture technology are significantly enhancing the primary cell culture market. These technologies provide more physiologically relevant models by better mimicking the in vivo environment compared to traditional 2D cultures. Innovations such as scaffold-based systems, spheroids, and organoids allow for more accurate cell-cell and cell-matrix interactions. This leads to improved disease modeling, drug screening, and tissue engineering applications. Moreover, 3D cultures support the growth of primary cells that retain their differentiated state and functionality, making them valuable for personalized medicine and regenerative therapies.
Reproducibility and standardization issues
In the primary cell culture market, reproducibility and standardization are critical challenges. Primary cells, derived directly from tissues, exhibit inherent biological variability, leading to inconsistent experimental outcomes. Standardization issues arise due to the lack of uniform protocols and quality controls, making it difficult to ensure consistency across different labs and experiments. Such challenges can hinder the reliability of research findings, affect the development of cell-based assays, and complicate regulatory approvals.
The COVID-19 pandemic significantly impacted the primary cell culture market, primarily through disruptions in supply chains and operational delays in laboratories. Increased demand for research related to SARS-CoV-2 spurred growth in the market, as primary cell cultures became crucial for studying virus behavior, developing vaccines, and testing antiviral drugs. Laboratories pivoted to COVID-19 research, which accelerated innovation and funding in cell culture technologies. However, the focus on pandemic-related studies also caused delays in non-COVID-19 research, affecting the overall research pipeline and project timelines.
The primary cells segment is expected to be the largest during the forecast period
The growth of the primary cells segment in the primary cell culture market can be attributed to several factors. There is increasing demand for more physiologically relevant cellular models for drug development and testing, which primary cells provide due to their direct extraction from tissues. This segment benefits from advancements in isolation techniques that preserve cellular integrity and function, enhancing their utility in research and clinical applications. Additionally, primary cells offer researchers the ability to study complex cellular interactions and disease mechanisms more accurately compared to immortalized cell lines.
The enzymatic degradation segment is expected to have the highest CAGR during the forecast period
Enzymatic degradation in the primary cell culture market is the process of using enzymes to dissociate cells from tissues or to degrade unwanted cellular components during cell culture. This segment's growth is driven by the increasing demand for efficient and gentle methods of cell isolation and maintenance. Enzymes such as trypsin, collagenase, and dispase are crucial in achieving high cell yields with minimal damage, thereby supporting various applications in research, drug development, and regenerative medicine. Advancements in enzyme technology, including the development of recombinant enzymes and improved formulations, further enhance the reliability and specificity of enzymatic degradation methods.
The North American region has experienced significant growth in the primary cell culture market due to several factors. First, there is increasing research and development activity in the biotechnology and pharmaceutical sectors, driving demand for primary cell culture techniques for drug discovery and development. The rising prevalence of chronic diseases and the need for personalized medicine have emphasized the importance of primary cell cultures in studying disease mechanisms and developing targeted therapies. Moreover, collaborations between academic institutions, research organizations, and industry players have contributed to the region's growth by facilitating knowledge exchange.
The Asia-Pacific region has witnessed significant growth in the primary cell culture market due to several factors. Increasing investments in the biotechnology and pharmaceutical industries across countries like China, India, Japan, and South Korea have driven demand. These nations are expanding their research capabilities and infrastructure, fostering a conducive environment for cell culture technologies. Additionally, the rising prevalence of chronic diseases has fuelled the need for advanced research in drug development, further boosting the market.
Key players in the market
Some of the key players in Primary Cell Culture market include American Type Culture Collection, Axol Bioscience Ltd., BioIVT, CGT Global, Corning Incorporated, Creative Bioarray, Cyagen , Danaher, Epithelix Sarl, FUJIFILM Wako Pure Chemical Corporation, HemaCare Corporation, Lonza Bioscience, Mattek, Merck KGaA, Neuromics, PPA Research Group, Inc., ReachBio LLC, STEMCELL Technologies, Thermo Fisher Scientific Inc. and XenoTech, LLC.
In February 2024, BioIVT announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks. Building on decades of human derived cell collection expertise, this additional capability enables BioIVT to further scale its world-class network of diverse, highly characterized donors and makes the company a leading provider of fresh leukopaks in the UK and mainland Europe.
In June 2024, Danaher Corporation has launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials. As part of the Danaher Beacons program, the multi-year collaboration aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.